Semaglutide: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Fix Cargo VARCHAR(300) overflow: blank structure, shorten mechanism, move chemistry/mechanism prose to PK/PD |
MDElliottMD (talk | contribs) Migrate <indication> tags to <problem> (Phase 2 of indications-to-problems rebuild) |
||
| Line 40: | Line 40: | ||
* 24% relative risk reduction in kidney + CV composite in T2DM + CKD (FLOW)<ref name="flow">Perkovic V et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). ''NEJM'' 391:109. doi:10.1056/NEJMoa2403347</ref> | * 24% relative risk reduction in kidney + CV composite in T2DM + CKD (FLOW)<ref name="flow">Perkovic V et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). ''NEJM'' 391:109. doi:10.1056/NEJMoa2403347</ref> | ||
| indications = < | | indications = <problem ref="diabetes-type-2" author="MDElliottMD"/> | ||
< | <problem ref="obesity" author="MDElliottMD"/> | ||
< | <problem ref="cv-risk-obesity" author="MDElliottMD"/> | ||
< | <problem ref="mash-fibrosis" author="MDElliottMD"/> | ||
< | <problem ref="ckd-t2dm" author="MDElliottMD"/> | ||
| dosing = <titration slug="ozempic-standard" author="MDElliottMD" title="Ozempic — standard T2DM titration"> | | dosing = <titration slug="ozempic-standard" author="MDElliottMD" title="Ozempic — standard T2DM titration"> | ||